Clinical trials are where medicines prove their worth before reaching patients, and Ireland has long underperformed in this arena. The Final Report of the National Clinical Trials Oversight Group, published on 21 November 2025 and approved by the Irish Government, sets out a 20-recommendation roadmap to transform Ireland’s clinical trials landscape. For pharmaceutical executives evaluating site selection, the report signals Ireland is closing the gap between its manufacturing reputation and its research record.

The reform agenda is overdue and the report deserves commendation for ambition and specificity. Ireland ranked 18th out of 27 EU member states for clinical trials per capita in 2024, sitting uncomfortably alongside its status as the world’s third-largest pharmaceutical exporter. The report addresses this on three fronts: strengthening governance, removing barriers to trial start-up, and embedding clinical research into standard hospital care.

The governance reforms are the most structurally significant. A Clinical Trials Advisory Council is to be established by early 2026, providing strategic oversight ahead of a National Clinical Trials Body by Q3 2027. The body will support sponsors and investigators, promote Ireland as a trials destination, and publish performance metrics. An open-access dashboard will track start-up times and activity, introducing transparency not currently available nationally.

The operational case is compelling. The IPHA Clinical Trials Activity Comparison Report from May 2025 found that pharma-sponsored trials rose 34% in 2024 and average time to first patient fell 31% to 46 days. Yet Denmark, of comparable size and wealth, conducted more than twice as many pharma-sponsored trials over the same period. Irish Cancer Society analysis confirms the pattern: Denmark runs three times more interventional cancer trials annually, a persistent disadvantage for sponsors.

The European dimension strengthens the case. The FAST-EU initiative, launched in November 2025, streamlines authorisation for multi-national trials through a collaborative assessment model across national competent authorities. Ireland’s participation, combined with universal contract templates and standardised costing frameworks proposed by the NCTOG, would reduce administrative friction that has historically deterred multi-site sponsors from including Irish centres. The EU Clinical Trials Regulation 536/2014 provides the legal foundation; Ireland now has the institutional plan to exploit it.

Three actions will determine whether the roadmap delivers. The Government should operationalise the Clinical Trials Advisory Council without delay, as the Q1 2026 target is already under pressure. Pharmaceutical sponsors should engage with the NCTOG’s unified online trials platform as it develops, ensuring site selection data and patient identification reflect commercial timelines. Hospital networks should designate protected consultant time for trial activity, which the NCTOG identifies as essential to embedding research into standard care.

The NCTOG report establishes a credible institutional pathway toward Ireland becoming a leading European clinical trials destination. Full implementation by 2027 would align with the EU Council Presidency that Ireland assumes in July 2026, lending practical weight to its life sciences ambitions. The prize is real: more trials mean faster patient access, stronger retention of clinical talent, and a deeper value chain for a sector that has excelled at manufacturing medicines but lagged at testing them.

(The views expressed by the writer are his/her own and do not necessarily reflect the views or positions of BusinessRiver.)